Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIII) Gains from Sales and Divestitures (2019 - 2022)

P3 Health Partners posted quarterly Gains from Sales and Divestitures of $5.0 million for Q4 2022, up 1.22% on a QoQ basis from $5.0 million in Q3 2022.

P3 Health Partners (PIII) has 4 years of Gains from Sales and Divestitures data on file, last reported at $5.0 million in Q4 2022.

  • For the quarter ending Q4 2022, Gains from Sales and Divestitures changed N/A year-over-year to $5.0 million; the trailing twelve-month figure through Dec 2022 stood at $5.0 million (changed N/A YoY), and the FY2022 full-year result was $5.0 million, changed N/A from the prior year.
  • Gains from Sales and Divestitures for Q4 2022 stood at $5.0 million, up from $5.0 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $5.0 million in Q4 2022 and bottomed at $443750.0 in Q4 2020.
  • The 4-year median for Gains from Sales and Divestitures is $660417.0 (2021), against an average of $2.5 million.
  • Peak annual rise in Gains from Sales and Divestitures reached 29.93% in 2020, while the deepest fall reached 29.93% in 2020.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $633333.0 in 2019, then decreased by 29.93% to $443750.0 in 2020, then soared by 48.83% to $660417.0 in 2021, then jumped by 662.85% to $5.0 million in 2022.
  • The last three Gains from Sales and Divestitures figures came in at $5.0 million (Q4 2022), $5.0 million (Q3 2022), and $4.9 million (Q2 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 HCA Healthcare 84.64 Bn 87.02 Bn 16.26 Bn
2 Tenet Healthcare 15.22 Bn 14.39 Bn 4.41 Bn
3 Davita 13.10 Bn 13.96 Bn 1.07 Bn
4 Encompass Health 10.50 Bn 11.12 Bn 1.34 Bn
5 Ensign 9.69 Bn 9.09 Bn 293.37 Mn
6 Universal Health Services 8.92 Bn 8.88 Bn 3.21 Bn
7 Fresenius Medical Care AG 7.31 Bn 4.93 Bn 22,843.10 Bn
8 Chemed 5.83 Bn 5.81 Bn 215.76 Mn
9 Pacs 5.76 Bn 5.51 Bn 345.96 Mn
10 P3 Health Partners 102.31 Mn 91.51 Mn 384.48 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 5.04 Mn
Dec 31, 2022 5.04 Mn
Sep 30, 2022 4.98 Mn
Sep 30, 2022 4.98 Mn
Jun 30, 2022 4.87 Mn
Jun 30, 2022 4.87 Mn
Mar 31, 2022 549,822.00
Mar 31, 2022 549,822.00
Dec 2, 2021 660,417.00
Dec 2, 2021 660,417.00
Dec 31, 2020 443,750.00
Dec 31, 2020 443,750.00
Dec 31, 2019 633,333.00
Dec 31, 2019 633,333.00